Tecfidera (dimethyl fumarate) is officially classified as an immunosuppressant. The European Medicines Agency places it in the pharmacotherapeutic group “immunosuppressants, other immunosuppressants.” But the full picture is more nuanced than that label suggests. Tecfidera works differently from traditional immunosuppressants, and its real-world effects on the immune system are generally milder, which is why you’ll also see it described as an “immunomodulator” in clinical literature.
Why the Classification Can Be Confusing
Tecfidera sits in an unusual middle ground. Its official drug code groups it with immunosuppressants, yet the same regulatory documents describe it as having “anti-inflammatory and immunomodulatory properties.” This isn’t a contradiction. The term immunosuppressant is a broad regulatory category, while immunomodulator describes how the drug actually behaves. Traditional immunosuppressants (like those used after organ transplants) broadly and aggressively shut down immune activity. Tecfidera instead adjusts the immune response, dialing down the overactive parts responsible for attacking nerve cells in multiple sclerosis while leaving much of the immune system functional.
In practice, neurologists often refer to Tecfidera as a moderate-efficacy immunomodulatory therapy. This distinction matters because it shapes expectations around side effects, infection risk, and how closely your immune system needs to be monitored.
How Tecfidera Affects the Immune System
Tecfidera’s active ingredient, dimethyl fumarate, works through at least two pathways. The first involves activating a protective system inside cells that reduces oxidative stress and inflammation. Dimethyl fumarate essentially switches off a protein that normally keeps this protective system dormant, releasing the cell’s built-in anti-inflammatory response. Research published in the Proceedings of the National Academy of Sciences found that this particular pathway may not fully explain the drug’s benefits in MS, suggesting dimethyl fumarate also works through additional, independent anti-inflammatory routes that scientists are still mapping out.
The second, more clinically visible effect is a reduction in white blood cells called lymphocytes. In clinical trials, lymphocyte counts dropped by about 30% during the first year of treatment. This is the main reason Tecfidera carries an immunosuppressant label. Fewer lymphocytes means a somewhat reduced ability to fight infections, though for most patients this reduction stays within a manageable range.
The Lymphocyte Drop and What It Means for You
That 30% average decline in lymphocytes is exactly that: an average. Most people on Tecfidera maintain lymphocyte levels well above the danger zone. However, about 5 to 6% of patients develop severe lymphopenia, where lymphocyte counts fall below 0.5 × 10⁹ cells per liter (roughly a quarter of the normal lower limit). Patients who are heading toward severe lymphopenia tend to show warning signs early, with a faster-than-average decline of more than 38% from baseline within the first three months.
This is why regular blood monitoring is non-negotiable on Tecfidera. The European Medicines Agency recommends a complete blood count before starting treatment and every three months afterward. If your lymphocyte count stays below 0.5 × 10⁹/L for more than six months, your doctor will likely reassess whether Tecfidera is still the right choice and may discontinue it.
Infection Risk in Practice
Despite the immunosuppressant classification, Tecfidera’s actual impact on infection rates is reassuringly modest. In clinical trials, 60% of patients on Tecfidera experienced some type of infection, compared to 58% on placebo. Serious infections occurred at the same rate in both groups: 2%. So for the majority of patients, Tecfidera does not meaningfully increase the risk of catching everyday illnesses.
The exception is patients who develop prolonged, severe lymphopenia. In those cases, the risk of a rare but serious brain infection called progressive multifocal leukoencephalopathy (PML) becomes a concern. PML is caused by a virus that most people carry harmlessly but that can reactivate when the immune system is significantly weakened. This is why the six-month lymphocyte threshold exists as a hard safety boundary. If any signs suggestive of PML appear, treatment is stopped immediately and permanently.
Vaccines and Tecfidera
Because Tecfidera has immunosuppressive properties, it affects vaccine decisions. The American Academy of Neurology recommends against using live-attenuated vaccines (such as the measles/mumps/rubella vaccine or the live shingles vaccine) while on Tecfidera or similar therapies. No studies have confirmed that live vaccines cause problems in this specific population, but the biological plausibility of risk in someone with a suppressed immune system is enough for most guidelines to advise caution.
Non-live vaccines, including flu shots and the COVID-19 mRNA vaccines, are generally considered safe. However, your immune response to any vaccine may be somewhat weaker while on Tecfidera, so timing vaccinations before starting treatment (when possible) can help maximize their effectiveness.
How Tecfidera Compares to Stronger Immunosuppressants
If you’re weighing Tecfidera against other MS therapies, understanding where it falls on the immunosuppression spectrum is useful. Drugs like fingolimod, alemtuzumab, and ocrelizumab suppress the immune system more aggressively and carry higher infection risks. Tecfidera is typically grouped with interferon and glatiramer acetate as a first-line or moderate-efficacy option, chosen when the goal is meaningful disease control without heavy-handed immune suppression.
The trade-off is that Tecfidera may not be potent enough for highly active MS. But for many patients, its balance of efficacy and manageable immune effects makes it a practical long-term option, provided blood counts are monitored consistently and stay within safe ranges.